Novo Nordisk A/S (NYSE:NVO) Shares Gap Down – Should You Sell?

Posted by Geri Gentry on Jul 31st, 2026

Novo Nordisk A/S (NYSE:NVO – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $51.61, but opened at $47.40. Novo Nordisk A/S shares last traded at $46.4860, with a volume of 8,333,939 shares.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Investors and retail commentators noted that Novo Nordisk’s current revenue drivers—including Ozempic and Wegovy—remain intact, meaning the failed trial does not directly affect existing GLP-1 sales. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
Positive Sentiment: Novo Nordisk’s collaboration with Crux is intended to broaden access to Wegovy through simpler benefit designs and more predictable pricing for U.S. employer health plans. The company also recently received European authorization for an oral Wegovy formulation, potentially supporting longer-term obesity-treatment growth. Novo Nordisk Teams Up With Crux to Expand Wegovy Access
Neutral Sentiment: Upcoming results remain focused on Ozempic and Wegovy sales, oral-product launches and label expansions, with investors watching whether these products can offset increasing competitive pressure. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
Negative Sentiment: The ZEUS trial’s failure removes a potentially valuable cardiovascular indication for ziltivekimab and raises concerns about the company’s pipeline diversification beyond its established diabetes and obesity franchises. The news prompted a broad selloff in NVO shares. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
Negative Sentiment: Analyst Erste Group Bank also reduced its fiscal 2026 earnings-per-share estimate to $3.20 from $3.22, below the $3.39 consensus estimate, adding to the cautious tone around Novo Nordisk’s outlook.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research analyst reports. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Five analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $65.56.

View Our Latest Stock Report on Novo Nordisk A/S

Novo Nordisk A/S Stock Performance

The firm has a market capitalization of $210.29 billion, a PE ratio of 11.05, a P/E/G ratio of 4.70 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The company’s fifty day simple moving average is $46.87 and its 200 day simple moving average is $45.49.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NVO. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $25,000. WealthCollab LLC increased its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the period. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $28,000. Jackson Grant Investment Advisers Inc. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $29,000. Finally, Maseco LLP purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $29,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.